Fluorouracil

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Fluorouracil

Examples of brand names: Fluorouracil medac [DE]

ATC code: L01BC02

Main use (for orientation): Oncology

Documented research summary

Historical THC antiemesis during 5-FU chemotherapy regimens is symptomatic supportive treatment, not pharmacokinetic or tumour-efficacy evidence. CBD/5-FU cell, nanocarrier and mucositis findings remain preclinical and formulation-specific.

Uncertainties and limitations

Intravenous FAVLYXA, label 09/2026; not topical 5-FU cream. Do not extrapolate topical CBD nanogel studies to intravenous use.

Shared enzymes must not be equated with clinical evidence of an interaction; CBD/THC findings cannot be extrapolated to other cannabinoids.

Separately recorded findings

3 separately recorded findings. Each statement applies to its documented study context.

CBD – laboratory and animal studies

Finding ID: B0228

Type of result: Preclinical evidence

Observation: CBD/5-FU co-formulations enhanced model cytotoxicity or local antitumour effects.

Mechanism: Formulation-dependent antitumour combination

Study type: Cell/in-ovo/formulation models

Context studied: Hyaluronic-acid liposomes or topical nanostructured lipid gels.

Clinical interpretation: Model finding, not a recommendation for use

Limitations and uncertainties: No evidence for oral CBD in addition to intravenous 5-FU.

Original sources for this finding: Hyaluronic Acid-Functionalized Liposomes for Co-delivery of 5-Fluorouracil and Cannabidiol Against Colorectal Cancer. [BMED41835056]; Advanced multifunctional nano-lipid carrier loaded gel for targeted delivery of 5-flurouracil and cannabidiol against non-melanoma skin cancer. [BMED37343751]; Formulation and development of novel lipid-based combinatorial advanced nanoformulation for effective treatment of non-melanoma skin cancer. [BMED36608807]

CBD – laboratory and animal studies

Finding ID: B0229

Type of result: Preclinical evidence

Observation: CBD reduced certain mucosal lesions and inflammatory/oxidative endpoints in mouse models; not all endpoints were significant.

Mechanism: Mucositis

Study type: Animal/cell models

Context studied: Nrf2/Keap1/ARE or intraperitoneal CBD doses of 3–30 mg/kg.

Clinical interpretation: Model finding, not a recommendation for use

Limitations and uncertainties: No clinical mucositis protection or dosage proposal.

Original sources for this finding: Protective Effects of Cannabidiol on Chemotherapy-Induced Oral Mucositis via the Nrf2/Keap1/ARE Signaling Pathways. [BMED35669853]; Cannabidiol on 5-FU-induced oral mucositis in mice. [BMED32400905]

THC – clinically investigated

Finding ID: B0231

Type of result: Clinical evidence – context-specific

Observation: Historical studies reported symptomatic antiemesis with THC during chemotherapy; no specific change in chemotherapy pharmacokinetics can be inferred.

Mechanism: Antiemetic supportive treatment

Study type: Historical controlled antiemetic studies

Context studied: Orr: 55 people receiving cyclophosphamide/5-FU/doxorubicin; do not count the 1980/81 reports independently. Frytak: 5-FU/semustine showed stronger CNS adverse effects with THC.

Clinical interpretation: Context-specific evidence

Limitations and uncertainties: Combination regimens; antiemesis is neither tumour efficacy nor general combination safety.

Original sources for this finding: Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine. [BMED6271846]; Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. [BMED6254456]; Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. [BMED517882]

References and access status

[V2_LABEL_D0411] FAVLYXA (FLUOROURACIL) INJECTION, SOLUTION [AVYXA PHARMA, LLC]

Original source / bibliographic reference

Authors: Avyxa Pharma, LLC

Year: 2026

Source type: Official US SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[BMED41835056] Hyaluronic Acid-Functionalized Liposomes for Co-delivery of 5-Fluorouracil and Cannabidiol Against Colorectal Cancer.

Original source / bibliographic reference

Authors: Abbaspour-Ravasjani S, Zeinali M, Asadollahi L, Safavi M, Mahoutforoush A, Talebi M, Hamishehkar H.

Year: 2025

Source type: Publication; title and abstract reviewed

DOI: 10.34172/apb.025.43401

PMID: 41835056

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[BMED37343751] Advanced multifunctional nano-lipid carrier loaded gel for targeted delivery of 5-flurouracil and cannabidiol against non-melanoma skin cancer.

Original source / bibliographic reference

Authors: Hasan N, Imran M, Sheikh A, Tiwari N, Jaimini A, Kesharwani P, Jain GK, Ahmad FJ.

Year: 2023

Source type: Publication; title and abstract reviewed

DOI: 10.1016/j.envres.2023.116454

PMID: 37343751

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[BMED35669853] Protective Effects of Cannabidiol on Chemotherapy-Induced Oral Mucositis via the Nrf2/Keap1/ARE Signaling Pathways.

Original source / bibliographic reference

Authors: Li L, Xuan Y, Zhu B, Wang X, Tian X, Zhao L, Wang Y, Jiang X, Wen N.

Year: 2022

Source type: Publication; title and abstract reviewed

DOI: 10.1155/2022/4619760

PMID: 35669853

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[BMED36608807] Formulation and development of novel lipid-based combinatorial advanced nanoformulation for effective treatment of non-melanoma skin cancer.

Original source / bibliographic reference

Authors: Hasan N, Imran M, Nadeem M, Jain D, Haider K, Moshahid Alam Rizvi M, Sheikh A, Kesharwani P, Kumar Jain G, Jalees Ahmad F.

Year: 2023

Source type: Publication; title and abstract reviewed

DOI: 10.1016/j.ijpharm.2022.122580

PMID: 36608807

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[BMED32400905] Cannabidiol on 5-FU-induced oral mucositis in mice.

Original source / bibliographic reference

Authors: Cuba LF, Salum FG, Guimarães FS, Cherubini K, Borghetti RL, de Figueiredo MAZ.

Year: 2020

Source type: Publication; title and abstract reviewed

DOI: 10.1111/odi.13413

PMID: 32400905

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[BMED38975420] NHS-Reimbursed Cannabis Flowers for Cancer Palliative Care and the Management of Chemotherapy-Induced Nausea and Vomiting: An Autobiographical Case Report.

Original source / bibliographic reference

Authors: Roberts M, Brown MRD, Moreno-Sanz G.

Year: 2024

Source type: Publication; title and abstract reviewed

DOI: 10.7759/cureus.61791

PMID: 38975420

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[BMED6271846] Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine.

Original source / bibliographic reference

Authors: Orr LE, McKernan JF.

Year: 1981

Source type: Publication; title and abstract reviewed

DOI: 10.1002/j.1552-4604.1981.tb02578.x

PMID: 6271846

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[BMED6095996] Metabolic studies of delta-9-tetrahydrocannabinol in cancer patients.

Original source / bibliographic reference

Authors: Frytak S, Moertel CG, Rubin J.

Year: 1984

Source type: Publication; title and abstract reviewed

PMID: 6095996

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

[BMED517882] Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo.

Original source / bibliographic reference

Authors: Frytak S, Moertel CG, O'Fallon JR, Rubin J, Creagan ET, O'Connell MJ, Schutt AJ, Schwartau NW.

Year: 1979

Source type: Publication; title and abstract reviewed

DOI: 10.7326/0003-4819-91-6-825

PMID: 517882

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[BMED6254456] Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis.

Original source / bibliographic reference

Authors: Orr LE, McKernan JF, Bloome B.

Year: 1980

Source type: Publication; title and abstract reviewed

DOI: 10.1001/archinte.140.11.1431

PMID: 6254456

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility